S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Germany urged to cap heat in offices this winter to save gas
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Germany urged to cap heat in offices this winter to save gas
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Germany urged to cap heat in offices this winter to save gas
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Germany urged to cap heat in offices this winter to save gas
The Financial Day of Reckoning Has Begun (Ad)
NASDAQ:NTLA

Intellia Therapeutics - NTLA Stock Forecast, Price & News

$67.74
+2.14 (+3.26%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$64.61
$68.82
50-Day Range
$38.49
$71.70
52-Week Range
$37.08
$180.59
Volume
813,844 shs
Average Volume
1.25 million shs
Market Capitalization
$5.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$128.00

Intellia Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.94 Rating Score
Upside/​Downside
89.0% Upside
$128.00 Price Target
Short Interest
Healthy
9.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.82mentions of Intellia Therapeutics in the last 14 days
Based on 23 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($5.83) to ($5.90) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

116th out of 1,135 stocks

Diagnostic Substances Industry

2nd out of 17 stocks

NTLA stock logo

About Intellia Therapeutics (NASDAQ:NTLA) Stock

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. StockNews.com upgraded shares of Intellia Therapeutics to a "sell" rating in a research report on Friday, August 5th. Oppenheimer cut their price objective on Intellia Therapeutics from $160.00 to $130.00 in a research note on Monday, May 9th. Bank of America began coverage on Intellia Therapeutics in a research report on Thursday, June 16th. They issued a "buy" rating and a $70.00 target price on the stock. SVB Leerink dropped their price target on Intellia Therapeutics from $155.00 to $152.00 and set an "outperform" rating for the company in a research report on Friday, August 5th. Finally, The Goldman Sachs Group decreased their price objective on Intellia Therapeutics from $206.00 to $180.00 and set a "buy" rating on the stock in a report on Tuesday, May 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $128.00.

Intellia Therapeutics Price Performance

NASDAQ:NTLA opened at $67.74 on Friday. The company's 50-day moving average is $57.34 and its two-hundred day moving average is $63.39. The firm has a market capitalization of $5.15 billion, a price-to-earnings ratio of -12.66 and a beta of 2.00. Intellia Therapeutics has a 1-year low of $37.08 and a 1-year high of $180.59.

Intellia Therapeutics (NASDAQ:NTLA - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($1.33) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.03). The business had revenue of $14.00 million during the quarter, compared to analyst estimates of $9.50 million. Intellia Therapeutics had a negative net margin of 883.17% and a negative return on equity of 40.23%. The company's revenue was up 115.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.01) earnings per share. As a group, equities analysts anticipate that Intellia Therapeutics will post -5.83 earnings per share for the current fiscal year.

Receive NTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NTLA Stock News Headlines

Intellia Therapeutics (NASDAQ:NTLA) PT Raised to $101.00
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at StockNews.com
Why Intellia Therapeutics Stock Is Sinking Today
Is It Time to Buy the Dip With Biotech Stocks?
See More Headlines
Receive NTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NTLA Company Calendar

Last Earnings
8/04/2022
Today
8/14/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NTLA
Fax
N/A
Employees
485
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$128.00
High Stock Price Forecast
$182.00
Low Stock Price Forecast
$54.00
Forecasted Upside/Downside
+89.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.94
Research Coverage
16 Analysts

Profitability

Net Income
$-267,890,000.00
Net Margins
-883.17%
Pretax Margin
-883.17%

Debt

Sales & Book Value

Annual Sales
$33.05 million
Book Value
$11.58 per share

Miscellaneous

Free Float
73,048,000
Market Cap
$5.15 billion
Optionable
Optionable
Beta
2.00














NTLA Stock - Frequently Asked Questions

Should I buy or sell Intellia Therapeutics stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last twelve months. There are currently 1 hold rating and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NTLA shares.
View NTLA analyst ratings
or view top-rated stocks.

What is Intellia Therapeutics' stock price forecast for 2022?

16 brokerages have issued 12 month target prices for Intellia Therapeutics' stock. Their NTLA share price forecasts range from $54.00 to $182.00. On average, they predict the company's share price to reach $128.00 in the next year. This suggests a possible upside of 89.0% from the stock's current price.
View analysts price targets for NTLA
or view top-rated stocks among Wall Street analysts.

How have NTLA shares performed in 2022?

Intellia Therapeutics' stock was trading at $118.24 on January 1st, 2022. Since then, NTLA stock has decreased by 42.7% and is now trading at $67.74.
View the best growth stocks for 2022 here
.

When is Intellia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our NTLA earnings forecast
.

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) issued its quarterly earnings results on Thursday, August, 4th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by $0.03. The business had revenue of $14 million for the quarter, compared to analysts' expectations of $9.50 million. Intellia Therapeutics had a negative trailing twelve-month return on equity of 40.23% and a negative net margin of 883.17%. The firm's revenue for the quarter was up 115.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.01) EPS.

What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?

12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an initial public offering on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (12.54%), FMR LLC (4.35%), Sumitomo Mitsui Trust Holdings Inc. (3.67%), Nikko Asset Management Americas Inc. (3.67%), Himension Capital Singapore PTE. LTD. (1.60%) and Northern Trust Corp (0.93%). Insiders that own company stock include Andrew Schiermeier, Caroline Dorsa, David Lebwohl, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Jose E Rivera, Jose E Rivera, Laura Sepp-Lorenzino and Perry A Karsen.
View institutional ownership trends
.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $67.74.

How much money does Intellia Therapeutics make?

Intellia Therapeutics (NASDAQ:NTLA) has a market capitalization of $5.15 billion and generates $33.05 million in revenue each year. The company earns $-267,890,000.00 in net income (profit) each year or ($5.35) on an earnings per share basis.

How many employees does Intellia Therapeutics have?

The company employs 485 workers across the globe.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The official website for the company is www.intelliatx.com. The company can be reached via phone at (857) 285-6200 or via email at lina.li@intelliatx.com.

This page (NASDAQ:NTLA) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.